Amarin Corp Plc (AMRN)

[ferretmoney]

Acasti will never succeed in getting a cardiovascular label (piggybacking on the Vascepa label). It’s a relatively small study (600 some participants) over a relatively short term (26 weeks). If they succeed in lowering triglycerides, so what? There is no established causal relationship. If they want the label they will have to run a large scale long-term outcomes study.